Time to sputum conversion in smear positive pulmonary TB patients on category I DOTS and factors delaying it

Journal of Association of Physicians of India

Volumn 60, Issue 8, 2012, Pages 22-26

  Parikh, Raunak ^a   Nataraj, Gita ^a   Kanade, Swapna ^a   Khatri, Vijay ^a   Mehta, Preeti ^a  

^a KEM HOSPITAL   (India)

Author keywords

[No Author keywords available]

Indexed keywords

TUBERCULOSTATIC AGENT;

ADULT; ARTICLE; DIRECTLY OBSERVED THERAPY; DRUG EFFECT; FEMALE; FOLLOW UP; GROWTH, DEVELOPMENT AND AGING; HUMAN; INDIA; ISOLATION AND PURIFICATION; LUNG TUBERCULOSIS; MALE; METHODOLOGY; MICROBIOLOGY; MIDDLE AGED; MYCOBACTERIUM TUBERCULOSIS; PROSPECTIVE STUDY; REGRESSION ANALYSIS; RISK FACTOR; SPUTUM; TEACHING HOSPITAL; TERTIARY HEALTH CARE; TIME; TREATMENT OUTCOME;

ADULT; ANTITUBERCULAR AGENTS; DIRECTLY OBSERVED THERAPY; FEMALE; FOLLOW-UP STUDIES; HOSPITALS, TEACHING; HUMANS; INDIA; MALE; MIDDLE AGED; MYCOBACTERIUM TUBERCULOSIS; PROSPECTIVE STUDIES; REGRESSION ANALYSIS; RISK FACTORS; SPUTUM; TERTIARY HEALTHCARE; TIME FACTORS; TREATMENT OUTCOME; TUBERCULOSIS, PULMONARY;

EID: 84865174623     PISSN: 00045772     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (35)

1. Centers for Disease Control and Prevention. Guidelines for preventing the transmission of Mycobacterium tuberculosis in healthcare settings, 2005. MMWR 2005;54[RR-17]:1-141.
2. Agarwal SP, Chauhan LS. Tuberculosis control in India. New Delhi, India: Directorate General of Health Services, Ministry of Health and Family Welfare, Government of India, 2005.
3. Sirgel AF, Odhiambo J, Girthui W, et al. A multicentre study of the early bactericidal activity of anti-tuberculosis drugs. J Antimicrob Chemother 2000;45:859-70.
4. Brindle R, Odhiambo J, Mitchison D. Serial counts of Mycobacterium tuberculosis in sputum as surrogate markers of sterilizing activity of Rifampicin and pyrazinamide in treating pulmonary tuberculosis. BMC Pulm Med 2001;1:2.
5. nd edition. Geneva, Switzerland: World Health Organisation, 2004.
6. Long R, Bochar K, Chomyc S, et al. Relative vervus absolute noncontagiousness of respiratory Tuberculosis on treatment. Infect Control Hosp Epidemiol 2003;24:823-838.
7. Telzak EA, Fazal BA, Pollard CL, et al. Factors influencing time to sputum conversion among patients with smear-positive pulmonary tuberculosis. Clin Infect Dis 1997;25:666-70.
8. Al-Moamary MS, Black W, Bessuille E, et al. The significance of the persistent presence of acid-fast bacilli in sputum smears in pulmonary tuberculosis. Chest 1999;116:726-731.
9. Gopi PG, Chandrasekaran, Subramani R, et al. Association of conversion and cure with initial smear grading among new smear positive pulmonary tuberculosis patients treated with catergory I regimen. Indian J Med Res 2006;123:807-814.
10. Singla R, Osman MM, Khan N, et al. Factors predicting persistent sputum smear positivity among pulmonary tuberculosis patients 2 months after treatment. Int J Tuberc Lung Dis 2003;7:58-64.
11. Wang JY, Lee LN, Yu CJ, et al. Factors influencing time to smear conversion in patients with smear-positive pulmonary tuberculosis. Respirology 2009;14:1012-1019.
12. Holtz TH, Sternberg M, Kammerer S, et al. Time to sputum culture conversion in multidrug-resistant tuberculosis: predictors and relationship to treatment outcome. Ann Intern Med 2006;144:650-659.
13. Guler M, Unsal E, Dursun B, et al. Factors influencing sputum smear and culture conversion time among patients with new case pulmonary tuberculosis. Int J Clin Pract 2007;61:231-235.
14. Dominguez-Castellano A, Muniain MA, Rodriguez-Bano J, et al. Factors associated with time to sputum smear conversion in active pulmonary tuberculosis. Int J Tuberc Lung Dis 2003;7:432-438.
15. Dembele SM, Ouedraogo HZ, Combary A, et al. Conversion rate at two-month follow-up of smear-positive tuberculosis patients in Burkina Faso. Int J Tuberc Lung Dis 2007;11:1339-1344.
16. Liu Z, Shilkret KL, Ellis HM. Predictors of sputum culture conversion among patients with tuberculosis in the era of tuberculosis resurgence. Arch Intern Med 1999;159:1110-1116.
17. Granich R, Binkin NJ, Jarvis WR, et al. Guidelines for the prevention of tuberculosis in healthcare facilities in resource-limited settings. Geneva: World Health Organization, 1999.
18. S top TB Department, World Health Organization. WHO Policy on TB infection control in healthcare-care facilities, congregate settings and households. Geneva, Switzerland: World Health Organization, 2009.
19. Central TB Division. Revised National Tuberculosis Control Program Technical and operational guidelines for tuberculosis control. New Delhi, India: Directorate General of Health Services, Ministry of Health and Family Welfare, Government of India, 2005.
20. nd edition. France, Paris: International Union Against Tuberculosis Control and Lung Disease, 2007.
21. World Health Organization. Laboratory services in tuberculosis control Part I, II and III. Geneva, Switzerland: World Health Organization,1998.
22. Central TB Division. Revised National Tuberculosis Control Program Manual for laboratory technicians smear microscopy for detection of acid-fast bacilli. New Delhi, India: Directorate General of Health Services, Ministry of Health and Family Welfare, Government of India, 2009.
23. World Health Organisation. WHO report 2009 Global Tuberculosis Control epidemiology, strategy, financing. Geneva, Switzerland: WHO Press, 2009.
24. Kim TC, Blackman RS, Heatwole KM, et al. Acid-fast bacilli in sputum smears of patients with pulmonary tuberculosis. Am Rev Respir Dis 1984;129:264-268.
25. Central TB Division. TB India 2009 Revised National Tuberculosis Control Program Status report. New Delhi, India: Ministry of Health and Family Welfare, Government of India, 2009.
26. Pachas AMC, Blank A, Fawzi MCS, et al. Identifying early treatment failure on Category I therapy for pulmonary tuberculosis in Lima Ciudad, Peru. Int J Tuberc Lung Dis 2004;8:52-58.
27. Jain A, Mondal R, Prasad R, et al. Prevalence of multidrug resistant Mycobacterium tuberculosis in Lucknow, Utter Pradesh. Indian J Med Res 2008;128:300-6.
28. D'souza DT, Mistry NF, Vira TS, et al. High levels of multidrug resistant tuberculosis in new and treatment-failure patients from Revised National Tuberculosis Control Programme in an urban metropolis (Mumbai) in Western India. BMC Public Health 2009;9:211.
29. Verver S, Warren R, Beyers N, et al. Rate of reinfection tuberculosis after successful treatment is higher than rate of new tuberculosis. Am J Respir Crit Care Med 2005;171:1430-1435.
30. Tripathy SP. Relapse in tuberculosis. Indian J Tuberc 1981;28:45-57.
31. Jasmer RM, Bozeman L, Schartzman K, et al. Recurrent tuberculosis in the United States and Canada Relapse or Reinfection. Am J Respir Crit Care Med 2004;170:1360-1366.
32. Cox H, Kebede Y, Allamuratova S, et al. Tuberculosis recurrence and mortality after successful treatment: impact of drug resistance. PLoS Med 2006;3:e384.
33. Bwire R, Borgdorff MW, Sticht-Groh V, et al. Tuberculosis chemotherapy and sputum conversion among HIV seropositive and HIV seronegative patients in south-earthern Uganda. East Afr Med J 1999;76:307-313.
34. Fitzwater SP, Caviedes L, Gilman RH, et al. Prolonged infectiousness of tuberculosis patients in a directly observed therapy short-course program with standardized therapy. Clin Infect Dis 2010;51:371-378.
35. Kuaban C, Bame R, Mouangue L, et al. Non conversion of sputum smears in new smear positive pulmonary tuberculosis patients in Yaoundé, Cameroon. East Afr Med J 2009;86:219-225.